These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36459735)

  • 1. Meta-Analysis on the Efficacy of Novel Glucose-Lowering Agents in Older Patients With Type 2 Diabetes Mellitus.
    Ahmed A; Imran L; Naeem U; Jawed A; Jawed A; Khan Z; Arshad AR; Arshad MS
    Am J Cardiol; 2023 Jan; 187():127-130. PubMed ID: 36459735
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.
    Bakris G
    J Fam Pract; 2019 Oct; 68(8):S1-S6. PubMed ID: 31697796
    [No Abstract]   [Full Text] [Related]  

  • 3. Meta-Analysis of Novel Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus Without Pre-existing Heart Failure.
    Ahmed A; Shahid I; Siddiqi AK; Ellahi A; Shurjeel Q; Rashid AM; Maniya T
    Am J Cardiol; 2022 Jul; 174():184-188. PubMed ID: 35504745
    [No Abstract]   [Full Text] [Related]  

  • 4. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis.
    Bloomgarden ZT; Dodis R; Viscoli CM; Holmboe ES; Inzucchi SE
    Diabetes Care; 2006 Sep; 29(9):2137-9. PubMed ID: 16936168
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes: intensive glucose-lowering therapy-weighing up the evidence.
    Cohen N
    Nat Rev Endocrinol; 2010 Jan; 6(1):9-10. PubMed ID: 20010962
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid improvement of psoriasis in diabetes subsequent to glucose lowering.
    Ogoshi M; Horikawa T
    Int J Dermatol; 2014 Feb; 53(2):e106-7. PubMed ID: 23432425
    [No Abstract]   [Full Text] [Related]  

  • 11. A modern approach to glucose-lowering therapy in frail older people with type 2 diabetes mellitus.
    Abdelhafiz AH; Pennells D; Sinclair AJ
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):95-98. PubMed ID: 35209779
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.
    Marrs JC
    Drugs Aging; 2012 May; 29(5):e1-e12. PubMed ID: 22530704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus.
    Chaturvedi N; Bilous R; Sjolie AK; Klein R;
    Contemp Clin Trials; 2007 Nov; 28(6):780. PubMed ID: 17643353
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of type 2 diabetes: future approaches.
    Bailey CJ; Day C
    Br Med Bull; 2018 Jun; 126(1):123-137. PubMed ID: 29897499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety.
    Fitchett D; Cheng A; Connelly K; Goldenberg R; Goodman SG; Leiter LA; Lonn E; Paty B; Poirier P; Stone J; Thompson D; Yale JF; Mancini GBJ
    Can J Cardiol; 2017 Jul; 33(7):940-942. PubMed ID: 28668144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
    Arnold SV; Echouffo-Tcheugui JB; Lam CSP; Inzucchi SE; Tang F; McGuire DK; Goyal A; Maddox TM; Sperling LS; Fonarow GC; Masoudi FA; Kosiborod M
    Am Heart J; 2018 Sep; 203():25-29. PubMed ID: 30015065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensified glucose lowering in type 2 diabetes: time for a reappraisal.
    Yudkin JS; Richter B; Gale EA
    Diabetologia; 2010 Oct; 53(10):2079-85. PubMed ID: 20686748
    [No Abstract]   [Full Text] [Related]  

  • 19. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
    Einecke D
    MMW Fortschr Med; 2005 Sep; 147(38):1. PubMed ID: 16218218
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.